,
The National Agency for Food and Drug Administration and Control (NAFDAC) has been informed by Pfizer Specialties Limited of the circulation of counterfeit Neo -Medrol in Nigeria.
Pfizer was informed of a video circulating on the internet advertising Neo Medrol in Nigeria bearing batch CDMPG and expiry date 02/2025.
According to Pfizer, the check conducted within Pfizer database indicates the batch number CDMPG is Pfizer batch for Neo Medrol distributed in August 2020.
Pfizer has withdrawn the registration of license for Neo Medrol in Nigeria in December 2021. The withdrawal of the registration license was due to global commercial decision that Pfizer took to seize manufacturing and commercialization of the product worldwide.
Neo Medrol is indicated for the topical treatment of acne vulgaris, acne rosacea and seborrheic dermatitis.
Genuine Neo Medrol is manufactured by Pfizer Specialties Limited. Pfizer have confirmed that the products referenced in this alert are falsified on the basis that they deliberately/fraudulently misrepresent their identity and source.
Product Details
| Brand Name | Batch No | Manufactured date | Expiry DATE |
| Neo Medrol | CDMPG | 01/2022 | 02/2025 |
The genuine Pfizer Neo- Medrol batch CDMPG has a manufacturing date on 19/03/2020 and expiry date on 31/01/2023.
The safety, sterility and quality of the falsified product referenced in this alert are unknown. This falsified product may therefore pose a particular high risk to patients. It is important to detect and remove these falsified products from circulation to prevent harm to patients.
All medical products must be approved and obtained from authorized/licensed suppliers. The product authenticity and physical condition should be carefully checked. Seek advice from a healthcare professional when in doubt.
NAFDAC implores importers, distributors, retailers, healthcare providers and patients in possession of the counfeit Neo -Medrol with manufacturing date 01/2022 and expiry date 02/2025 to discontinue sale or use, handover stock to the nearest NAFDAC office.
Healthcare providers and patients are encouraged to report drug reaction and substandard and falsified medicines to NAFDAC on 0800-162-3322 or email: sf.alert@nafdac.gov.ng, E-reporting platforms available on the NAFDAC website or via the Med- safety application for download on android and IOS stores.
NAFDAC……..Customer-focused, Agency-minded!!!
Signed Management
